Byondis
Gerrit Voortman has extensive experience in the pharmaceutical and biotechnology industries, demonstrating a strong background in clinical development, regulatory affairs, and corporate development. Voortman has served as Vice President of Corporate Development and Vice President of Regulatory Affairs at Byondis since October 2014. Prior roles include Vice President of Clinical Development and Director of Medical R&D at Synthon, Owner of Drug & Device Development Consultancy (3DC), Chief Scientific Officer (Acting) at M et P Pharma, and Director of Clinical Research at Clinquest Europe BV. Additional experience includes positions at Medtronic, Organon, and Organon Pharmaceuticals, where Voortman managed development projects and clinical studies. Voortman holds a Master's degree in Toxicology from Open Universiteit, completed between 1988 and 1995.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.